Anzeige
❌
Mehr »
Donnerstag, 19.11.2026 - Börsentäglich über 12.000 News
Folge dem Geld: Methan im Fokus der COP31!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

Aktuelle News von FierceBiotech

  • 24 h
  • letzte 200 News
ZeitAktuelle Nachrichten
03.11.Abbott's Tectonic test looks to shift artery disease treatment with 'early' win
03.11.Rhythm doubles down on LG Chem obesity license, raising payout to as much as $855M
03.11.Philips sets aside $322M for proposed DOJ settlement over sleep apnea device recall
03.11.AbbVie abandons phase 2 solid tumor drug over 'limited benefit'
03.11.Pfizer pares back obesity pipeline, drops phase 2-stage lung disease candidate
03.11.BioArctic left out in the cold as Novartis walks away from $800M neuro collab
02.11.FDA grants uniQure's Huntington's gene therapy priority review, teeing up 'defining milestone'
02.11.OpenAI-funded Biossil snags Theriva's unwanted antibiotic degrader portfolio for up to $91M
02.11.Teva ends trial of one of its original line-up of innovative meds over futility
02.11.FDA dims Bright Minds' outlook with partial hold on seizure trial over toxicity in mice
02.11.Lower dose of Tiziana's MS drug reduces neuroinflammation, while higher dose struggles
02.11.China's InventisBio delivers competitive TYK2 data in phase 3 psoriasis win
30.10.Gilead reveals partial clinical hold on 2 CAR-T cell therapy trials
30.10.Bracco invests $230M in first US diagnostic imaging manufacturing facility
30.10.When drug development gets personal
30.10.Chutes & Ladders-Lilly unifies global markets as 36-year vet Patrik Jonsson retires
30.10.Jazz's $820M Actio buyout gives rise to Setara, armed with $90M series A
30.10.AstraZeneca cuts early-phase prostate cancer pipeline
30.10.Molecular Partners to lay off up to 44% of workforce in radiotherapy pivot
30.10.Bambusa shoots past IPO targets as Aspen trims offering
30.10.Sanofi considering 'moonshot' treatments as M&A targets to survive Dupixent patent cliff
30.10.Roche launches differential diagnosis test for mesothelioma
29.10.Connected clinical research: from fragmentation to progress
29.10.Eli Lilly scraps phase 2 Alzheimer's program after drug falls short of expectations
29.10.The cost of waiting: What reaching clinical proof-of-concept sooner means for biotech cash burn